Vitamin D receptor (VDR) agonist; analog of calcitriol
(Cat. No. 2551). Exhibits anti-tumor and anti-proliferative activity with reduced hypercalcemic effects. 60 times more potent in inhibiting MCF-7 cell growth in vitro
; also shown to induce autophagy in MCF-7 cells. Reverses the effects of parathyroid hormone-related protein (PTHrP).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.
Lu et al.
Mol.Cancer Ther., 2008;7:1268
EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
Bhatia et al.
Mol.Cancer Ther., 2009;8:1787
Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death.
Hoyer-Hansen et al.
Cell Death Differ., 2005;12:1297
Reversal of hypercalcaemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
Abdaimi et al.
Cancer Res,, 1999;59:3325
The citations listed below are publications that use Tocris products. Selected citations for EB 1089 include:
Showing Results 1 - 2 of 2